BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AtCor Medical Pty Ltd Announces New $0.6 Million Pharmaceutical Clinical Trials Contract


3/15/2011 9:59:57 AM

ITASCA, IL--(Marketwire - March 15, 2011) - AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system, which measures central blood pressures and arterial stiffness noninvasively, today announced that it has signed a new $0.6 million agreement to supply SphygmoCor systems and clinical trial support services in a new drug trial conducted by a major international pharmaceutical company.

Detecting potentially beneficial and detrimental effects on central pressures

Duncan Ross, CEO of AtCor Medical, said, "Over the past five years, there has been mounting evidence of potentially beneficial and detrimental drug effects on central blood pressures and arterial stiffness.* We are especially pleased that, as exemplified in this clinical trial, noninvasive central pressure assessment has grown beyond hypertension medications to encompass studies of drug effects of new and existing drug therapies in many drug classes. Noninvasive measurement of central blood pressures and arterial stiffness allows pharmaceutical companies and clinicians to more fully understand drug benefits and potential risks."

"The growing recognition of the importance of central blood pressure assessment has been an important contributor to AtCor Medical's growth," Ross continued. "In the past 12 months, we have signed contracts for 9 new clinical trials and 4 study extensions. Our clients include leading international pharmaceutical companies and entrepreneurial drug and device companies. We are especially proud of our customers' response to the quality of the training, investigator site support, and information management technology we have incorporated as integral elements of our clinical trials offering. We truly offer a turnkey solution for the assessment of central pressures and arterial stiffness in clinical trials, working with trial sponsors and CROs, not as a supplier but as a trusted member of the team.

About AtCor Medical

AtCor Medical's SphygmoCor systems are the gold standard for noninvasive assessment of central blood pressure and arterial stiffness, used globally in every stage of clinical trials and in clinical practice, featured in over 600 published studies.

With SphygmoCor systems, the central blood pressure waveform, determined noninvasively from the radial artery waveform, provides critical reflected pressure data, used in assessing drug effects in trials, and in drug selection and therapy management by clinicians. AtCor provides comprehensive clinical trial support: SphygmoCor systems with PWA, PWV and HRV capabilities, trial site training, data quality assurance and data management using the AtCor WISDOM system.

More than 2,100 SphygmoCor systems are currently in use worldwide in major medical centers, research institutions, physicians' offices and in pharmaceutical clinical trials. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com

*Camafort-Babkowski Choosing an Antihypertensive Combination with a More Efficient Central Blood Pressure Reduction Expert Rev Cardiovascular Ther 2010; 8 (11):1523-1525


For further information, please contact:
Duncan Ross
AtCor Medical CEO
(630) 228-8873

Larry Watts
AtCor Director, Marketing Services
(630)228-8875
info@atcormedical.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES